Peculiar features of immunoinflammatory syndrome in patients with ulcerous colitis, depending on severity of disease attack

Cover Page

Cite item

Full Text

Abstract

Aim. To study the blood serum interleukin-6 (IL) and circulating immune complexes (CIC) levels in patients with ulcerous colitis (UC), depending on the severity of disease attack, colonic inflammation dissemination, and presence of abenteric manifestations.

Materials and methods. One hundred patients with UC in the phase of active inflammation were examined. Blood serum IL-6 and CIC concentrations were studied with IFA method.

Results. 88,5 % of UC patients in the phase of active inflammation showed an elevated mean IL-6 index, 80 % had increased CIC concentration as compared with normal values. The highest IL-6 and CIC levels were obtained in case of severe forms of disease (11,50 (7,30–23,65) pg/ml and 115,50 (105,00–118,00), respectively); CIC and IL-6 levels were significantly higher in patients with abenteric manifestations and frequently relapsing course in comparison with patients, having rare UC relapses (p < 0,005). Strong direct correlations of IL-6 and CIC with each other (r = 0,65; p = 0,001) as well as with the severity of pathological changes in the colon were established.

Conclusions. Among patients with UC, significantly elevated blood serum IL-6 and CIC concentrations were determined. Patients with severe attack of disease as well as those with abenteric manifestations and frequent relapses demonstrated reliably higher levels of these indices. It is recommended to use determination of blood serum IL-6 and CIC levels as an available and informative method, permitting to estimate the degree of severity of inflammatory process in the colonic wall among patients with ulcerous colitis.

About the authors

Yu. I. Tretyakova

Academician Ye.A. Vagner Perm State Medical University

Author for correspondence.
Email: tretyakovayi@gmail.com

кандидат медицинских наук, доцент кафедры поликлинической терапии

Russian Federation, 26, Petropavlovskaya str., Perm, 614000

References

  1. Булатова И.А., Щекотова А.П., Кривцов А.В., Щекотов В.В., Насибуллина Н.И., Калугина Е.А. Фактор некроза опухоли альфа, циркулирующие иммунные комплексы и фагоцитоз при хроническом гепатите С. Пермский медицинский журнал 2014; 31(2): 68-72.
  2. Долгов В.В., Ракова В.В., Колупаев В.Е., Рытикова Н.С. Иммуноферментный анализ в клинико-диагностических лабораториях. М. - Тверь: ООО «Триада» 2007; 320.
  3. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология 2017; 59 (1): 6-30.
  4. Мухаметова Д.Д., Абдулганиева Д.И., Зинкевич О.Д., Сафина Н.А., Одинцова А.Х. Иммунный ответ к кишечной микробиоте при воспалительных заболеваниях кишечника. Практическая медицина 2014; 1(77): 103-107.
  5. Осадчая О.И., Боярская А.М. Влияние энтеросорбции на развитие гуморальных реакций иммунитета у больных с неспецифическим язвенным колитом. Новости медицины и фармации. Медицина сегодня 2011; 11-12: 371-372.
  6. Сагынбаева В.Э., Лазебник Л.Б. Повышение содержания циркулирующих иммунных комплексов C1q и C3d как критерий обострения внекишечных проявлений язвенного колита. Экспериментальная и клиническая гастроэнтерология. 2014;107 (7): 18-24.
  7. Совалкин В.И., Бикбавова Г.Р., Емельянова Ю.А. Современный взгляд на патогенез и лабораторную диагностику язвенного колита (обзор литературы). Архив внутренней медицины 2017; 4: 252-259.
  8. Emmrish J. Monoclonal antibodies and interleukins. Falk Symposium (Innovative concepts in inflammatory bowel disease) 2002; 105: 74.
  9. Iqbal T., Stein J., Sharma N., Kulnigg-Dabsch S., Vel S., Gasche C. Clinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia. Dig Dis Sci 2015; 60(5): 1375-1381.
  10. Kaser A., Nieuwenhuis E., Glimcher. Innate immunity in inflammatory bowel disease. Falk symposium 2006; 23-24.
  11. Kostić M., Djakovic L., Šujić R., Godman B., Janković S. Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. Appl Health Econ Health Policy 2017; 15 (1): 85-93.
  12. Lee M. J., Lee J., Choi J. W., Lee C. Interleukin-6 Induces S100A9 Expression in Colonic Epithelial Cells through STAT3 Activation in Experimental Ulcerative Colitis PLoS One 2012; 7(9): e38801. doi: 10.1371/journal.pone.0038801
  13. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041-1048.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. Structure (%) concentration in patients with UC: a - IL-6; b - CEC

Download (121KB)

Copyright (c) 2018 Tretyakova Y.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies